AIDS Clinical Trial
Official title:
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
Background:
Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also
co-infected with HCV. Thus, hemophiliacs represent an important population for studies of the
natural history of these chronic viral infections.
Moreover, the high rate of co-infection makes it an ideal group for assessing the interaction
between the viruses and the relationship between viral specific immune responses and clinical
progression.
Although the hemophiliac poulation is unique, co-infection by these chronic viral pathogens
is becoming increasingly common, particularly amongst intravenous drug users, who account for
approximately 25% of the HIV-1 epidemic in the United States.
Objectives:
The aim of this study is to determine if polymorphism in the promoter region of TH1 and Th2
cytokines are associated with (1) intracellular cytokines levels in CD4 + Tcells, (2) Human
Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) viral loads, and (3) clinical
progression of HIV1 to AIDS in hemophiliacs.
Eligibility:
The current proposal will investigate host genetic factors related to HIV-1 and HCV
immunopathogenesis by studying children and adolescents enrolled in the Hemophilia Growth and
Development Study (HGDS).
Design:
This study is in collaboration with the principle investigators of the Hemophilia Growth and
Development Study (HGDS) as part of a grant "Pathogenesis of HIV and HCV in Hemophilia:
HGDS-3" with funding support by NIH/NICHD for the period 9/25/01 through 8/31/2005.
This multicenter, United States study represents a well-characterized, prospectively followed
cohort of HCV-infected hemophiliacs, of whom 207 are HIV-1 co-infected.
Enrollment of the hemophiliac cohort was completed between 3/89 and 6/90. The final
observation of the cohort (follow-up 16) was concluded during 7/98. No new samples or
clinical data will be collected on this population.
The LGD plays two roles in this project: (1) an administrative role overseeing the
withdrawal, handling, and transport of samples from the HGDS/LGD and central repositories at
the NCI-Frederick, and (2) a scientific role continuing investigations to determine the role
of host genetic factors in Th1 and Th2 immune response and regulation of HCV and HIV viral
replication..
Background:
Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also
co-infected with HCV. Thus, hemophiliacs represent an important population for studies of the
natural history of these chronic viral infections.
Moreover, the high rate of co-infection makes it an ideal group for assessing the interaction
between the viruses and the relationship between viral specific immune responses and clinical
progression.
Although the hemophiliac poulation is unique, co-infection by these chronic viral pathogens
is becoming increasingly common, particularly amongst intravenous drug users, who account for
approximately 25% of the HIV-1 epidemic in the United States.
Objectives:
The aim of this study is to determine if polymorphism in the promoter region of TH1 and Th2
cytokines are associated with (1) intracellular cytokines levels in CD4 + Tcells, (2) Human
Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) viral loads, and (3) clinical
progression of HIV1 to AIDS in hemophiliacs.
Eligibility:
The current proposal will investigate host genetic factors related to HIV-1 and HCV
immunopathogenesis by studying children and adolescents enrolled in the Hemophilia Growth and
Development Study (HGDS).
Design:
This study is in collaboration with the principle investigators of the Hemophilia Growth and
Development Study (HGDS) as part of a grant "Pathogenesis of HIV and HCV in Hemophilia:
HGDS-3" with funding support by NIH/NICHD for the period 9/25/01 through 8/31/2005.
This multicenter, United States study represents a well-characterized, prospectively followed
cohort of HCV-infected hemophiliacs, of whom 207 are HIV-1 co-infected.
Enrollment of the hemophiliac cohort was completed between 3/89 and 6/90. The final
observation of the cohort (follow-up 16) was concluded during 7/98. No new samples or
clinical data will be collected on this population.
The LGD plays two roles in this project: (1) an administrative role overseeing the
withdrawal, handling, and transport of samples from the HGDS/LGD and central repositories at
the NCI-Frederick, and (2) a scientific role continuing investigations to determine the role
of host genetic factors in Th1 and Th2 immune response and regulation of HCV and HIV viral
replication..
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Completed |
NCT02606344 -
Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV
|
N/A | |
Completed |
NCT01053598 -
Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting
|
N/A | |
Completed |
NCT01348308 -
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00951795 -
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
|
N/A | |
Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
Withdrawn |
NCT00347750 -
Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations
|
Phase 3 | |
Withdrawn |
NCT00340223 -
HLA-B35 Alleles and AIDS
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Completed |
NCT00144352 -
In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults
|
Phase 4 | |
Completed |
NCT01084395 -
Reducing HIV Risk Among Mexican Youth
|
N/A | |
Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
Completed |
NCT00341172 -
The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
|
||
Recruiting |
NCT06145841 -
Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
|
||
Completed |
NCT03633721 -
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women
|
Phase 2 | |
Completed |
NCT04567693 -
Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV
|
N/A | |
Completed |
NCT03023033 -
Supporting Attendance for Facility Delivery and Infant Health
|
N/A |